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ABSTRACT
Objective: To facilitate development and evaluation of a PRO instrument
conceptual framework, we propose two tools—a PRO concept taxonomy
and a PRO instrument hierarchy. FDA’s draft guidance on patient
reported outcome (PRO) measures states that a clear description of the
conceptual framework of an instrument is useful for evaluating its
adequacy to support a treatment beneﬁt claim for use in product labeling
the draft guidance, however does not propose tools for establishing or
evaluationg a PRO instrument’s conceptual framework.
Methods: We draw from our review of PRO concepts and instruments
that appear in prescription drug labeling approved in the United States
from 1997 to 2007.
Results: We propose taxonomy terms that deﬁne relationships between
PRO concepts, including “family,” “compound concept,” and “singular
concept.” Based on the range of complexity represented by the concepts,
as deﬁned by the taxonomy, we propose nine instrument orders for PRO
measurement. The nine orders range from individual event counts to
multiitem, multiscale instruments.
Conclusion: This analysis of PRO concepts and instruments illustrates
that the taxonomy and hierarchy are applicable to PRO concepts across a
wide range of therapeutic areas and provide a basis for deﬁning the
instrument conceptual framework complexity. Although the utility of
these tools in the drug development, review, and approval processes has
not yet been demonstrated, these tools could be useful to improve com-
munication and enhance efﬁciency in the instrument development and
review process.
Keywords: classiﬁcation system, conceptual framework, patient-reported
outcomes, PRO concept taxonomy, PRO instrument hierarchy.
Introduction
The 2006 Food and Drug Administration draft guidance on
patient-reported outcome (PRO) measures states that one of the
ﬁrst steps in the instrument selection or development process is
the identiﬁcation of the conceptual framework of each instru-
ment [1]. The framework speciﬁes the purpose for each item in
terms of the instrument’s measurement goal and speciﬁes how
each item is to be used, either as a single-item concept or grouped
together to form more complex concepts scored according to the
instrument’s measurement structure and scoring system. The
instrument can be deemed adequate to support a targeted state-
ment of treatment beneﬁt (i.e., claim) if the instrument measures
the claimed concept in a well-deﬁned and reliable way. By rec-
ommending the speciﬁcation of the conceptual framework for
each instrument, FDA recognizes the extensive variation that
exists among PRO instruments. The tools described here offer a
systematic approach to establishing and evaluating any instru-
ment’s conceptual framework.
Instruments used in clinical research studies are known to
differ in content depending on their intended application, for
example, diagnosis, disease severity, and patient characteristics.
These factors, in turn, determine the most relevant concepts for
measuring treatment impact. Instruments may also differ accord-
ing to developers’ perspectives on how to represent PRO con-
cepts and their relationships; for example, researchers trained in
medicine, psychology, and economics have developed instru-
ments with different item formats, content, measurement struc-
tures, and scoring systems [2–5]. Reviews of compendia of health
status and well-being measures present a more complete perspec-
tive of the diversity of concepts and measurement structures used
in generating scoring systems for measures used in various ﬁelds,
including pharmacoeconomics, health services research, geriat-
rics, mental health, and nursing [6–11].
Within the PROﬁeld, researchers, including Fries, Guyatt, and
Spilker [12–14], have proposed taxonomies for classifying health-
related quality-of-life (HRQoL) concepts; these systems, however,
have not as yet been operationalized. Existing classiﬁcation opera-
tional systems, such as the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV), International Statis-
tical Classiﬁcation of Diseases and Related Health Problems
(ICD), and International Classiﬁcation of Functioning, Disability,
andHealth (ICF), [15–19], illustrate the clustering of concepts and
diagnoses and their hierarchical arrangement into concepts of
increasing complexity. These, however, have been designed for
enumeration and epidemiologic analysis rather than for the type
of evaluative decision-making required in the drug approval
process. Our review of labeling approved by FDA indicated that
PRO instruments of different complexities, from single items of
event counts to multiitem, multiconcept instruments have been
used to support claims of treatment beneﬁt [20]. Furthermore, this
review suggested that it would be possible to link an instrument’s
content andmeasurement structure to the nature of a statement of
treatment beneﬁt. That is, there is an interrelationship between the
intended claim and the measure that supports it.
The ability to identify and codify this relationship has several
advantages to sponsors, regulators, as well as to outcomes
researchers more broadly. First, the sponsor and FDA need to
understand the complexity of the concept in the desired claim
because it will determine the adequacy of the instrument used to
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support that claim. From FDA’s point of view, more complex
claims are likely to require more comprehensive instruments that
have been demonstrated to capture all the important aspects of
the complex concept in the targeted patient population [21].
Second, matching the complexity of the claim to patients’ and
physicians’ perspectives of disease burden and impact can be
important to the external credibility and effect of the claim.
Third, being able to link a PRO instrument explicitly to regula-
tory or clinical decision-making via the conceptual framework
can be both a rewarding and challenging aspect of study design
and implementation. Moreover, speciﬁcation of the relationship
between a statement of treatment beneﬁt and the PRO instru-
ment that supports this claim incorporates the need for using
standard, well-established psychometric methods to demonstrate
properties, such as content and construct validity, as integral
components of the decision-making process.
To set forth a systematic method for depicting an instrument’s
conceptual framework, this article proposes a “PRO Concept
Taxonomy” and a “PRO Instrument Hierarchy.” These two
tools endeavor to resolve inconsistency and confusion when con-
ceptualizing and quantifying treatment beneﬁt measured by PRO
instruments. The PRO Concept Taxonomy incorporates key
terms, including “singular” concept, “compound” concept, and
“family” concept; usage of these terms is proposed as a way of
adding clarity to the development of an instrument’s conceptual
framework. This proposed classiﬁcation system is generalizable
across a wide range of families and concepts.
The PRO Instrument Hierarchy connects the conceptual
content of a PRO instrument that has been selected to support
the intended claim with the instrument’s measurement structure
and scoring system, thereby completing the description of the
instrument’s conceptual framework. By linking the claim made
with the complexity of the instrument used to support it, we can
plan a measurement strategy for future labeling goals.
Methods for Developing the PRO Concept
Taxonomy and PRO Instrument Hierarchy
The ﬁrst step in developing the taxonomy and hierarchy was to
evaluate PRO concepts that were identiﬁed in our review of the
Clinical Studies sections of the labeling for 215 new products
approved in the United States from January 1997 through
December 2002 [20]; labeling for 64 of these products was found
to report at least one PRO. We attempted to identify the actual
PRO instrument used to measure the PRO concept and each
instrument was evaluated in terms of its conceptual framework
to determine the instrument’s relationship to the PRO concept
identiﬁed. In this article, we use the term “concept” to refer to an
aspect of how patients feel or function that is expressed qualita-
tively; when measured by a PRO instrument, a concept is repre-
sented by items and domains.
The second step was to validate the taxonomy and hierarchy
by evaluating the labeling for the 142 new products approved
by FDA from January 2003 through December 2007; labeling
for 36 products reported at least one PRO. The PRO concepts
and instruments found in labeling for the 1997–2007 period
can be found at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12i8_Erickson.asp. The same methods
were used for this review as for that of the 1997–2002 labeling.
Third, we broadened the scope of our evaluation of PRO instru-
ments to include formal scales beyond those that appeared in the
new product labeling using information from the On-Line Guide
to Quality-of-Life Assessment (OLGA) [6,22]. OLGA’s compre-
hensive database includes information on thousands of instru-
ments that are of potential relevance for supporting a claim of
treatment beneﬁt. Based on selection criteria designed to identify
instruments of diverse conceptual content and measurement
structures, the conceptual frameworks of 25 instruments were
formally evaluated. This step provided assurance that the tax-
onomy and hierarchy would be relevant not only to instruments
used in previous labeling, but also to those that might appear
after 2007.
These evaluations indicated that to fully understand the
concept, or concepts, measured by a single instrument or battery
of instruments, it is necessary to understand the relationships
between the included concepts within the context of their use in
the intended claim. For example, a claim of treatment beneﬁt for
a new migraine product is commonly stated in terms of ﬁve
separate symptoms (deﬁned below). Because there is no explicit
speciﬁcation of an interrelationship between them, ﬁve symptom-
speciﬁc instruments are used to provide an implicit, rather than a
measured, statement about treatment impact of the more general
concept of migraine symptoms.
On the other hand, arthritis-related physical function is fre-
quently expressed in terms of abilities to perform everyday acti-
vities, such as basic activities of daily living (ADLs) and
instrumental ADLs (IADLs), for example, shopping, managing
money, doing heavy housework, and mobility. When the rela-
tionships between the general and speciﬁc concepts is explicitly
recognized, they can be measured using a single instrument, such
as the Health Assessment Questionnaire Disability Index (HAQ-
DI) [23], and the obtained scores can provide explicit informa-
tion about treatment impact on both the more general concept as
well as the speciﬁc abilities.
The PRO Concept Taxonomy
As a result of our evaluation of instruments, we deﬁne four
nested levels of concepts that represent a practical limitation on
the number of levels relevant for making meaningful statements
about treatment beneﬁt using PROs, a ﬁfth level we deﬁne as
concepts that are too basic for supporting meaningful claims (see
Fig. 1). Concepts in lower levels of the nested arrangement are
more speciﬁc than those in the higher levels. Understanding
relationships between concepts enables researchers to apply an
instrument that is appropriate for the purpose of measurement.
To facilitate a systematic method for depicting a conceptual
framework, we deﬁne three terms: “family,” “compound
concept,” and “singular concept.” A family is a taxonomic cat-
egory that consists of subcategories, much like species and sub-
species in biology. In the PRO context, families can be thought of
as higher-level concepts that have subconcepts consisting of com-
pound and singular concepts.
Families may be either generic or speciﬁc with respect to
disease or condition. Generic families, such as mental, physical,
and social function [24–26] are too general for meaningful,
product-related discussions and measurement. Speciﬁc families,
on the other hand, categorize concepts that are related to key
diagnostic and therapeutic aspects and, thus, are useful for dis-
cussing treatment beneﬁt; each speciﬁc family can be placed
within a generic family. For example, the speciﬁc family of
migraine symptoms, which is traditionally deﬁned in terms of
nausea, vomiting, pain, phonophobia, and photophobia, is
located within the generic family of signs and symptoms.
Each family, whether generic or speciﬁc, comprises at least
one singular concept that both patients and their health-care
decision-makers could consider to be a meaningful goal of treat-
ment beneﬁt, for example, pain intensity. Singular concepts may
have low-level singular concepts that are considered to be too
basic for use in labeling, for example, ability to cut meat. A
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compound concept is deﬁned as consisting of at least two singu-
lar concepts; for example, the concept “basic activities of daily
living” typically includes bathing, toileting, transferring, and
dressing.
The PRO Concept Taxonomy is intended to provide structure
to the task of establishing and reviewing a conceptual frame-
work. This task requires identiﬁcation of the concepts repre-
sented by instrument scores, identifying all items that contribute
to that score, and diagramming the nesting of concepts within
one or more families where appropriate, as illustrated in
Figure 2. Singular concepts, and low-level singular concepts, are
the most fundamental units in the taxonomy and can be consid-
ered as the “building blocks” of compound concepts. A com-
pound concept may be made up of two types of singular
concepts: 1) those that include low-level singular concepts, as
shown in Family 1; and 2) those that can be measured with one
item, as shown in Family 2. The type and number of these
singular concepts depends on the disease and its treatment as well
as the compound concept that represents the goal of measure-
ment and corresponds to the labeling targets. A statement of
beneﬁt may be based on information about a single family or
multiple families.
Low-level singular concepts: an aspect 
of a singular concept that are too basic 
to be used for a claim of treatment 
benefit, e.g., shampooing hair
Singular concept: the most specific aspect 
of health or well-being that is meaningful 
to patient and health professionalM
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Compound concept: includes at least 2 
singular concepts that are identifiable 
subsets, e.g., ADL
Family  (generic): an overarching category
that refers to a group related elements, or 
concepts, e.g., physical function
Aggregate: a compound concept 
composed of multiple families
Family (specific): a narrowly defined 
family that is usually described in terms 
of either a disease or health condition, 
e.g., migraine symptoms
Family 1 (F1) Family 2 (F2)
Aggregate
Specific F1 Specific F2
Level 1
Level 2
Level 4
Level 3
Figure 1 Patient-reported outcome concept taxonomy: depicts relationships between concepts.ADL, activity of daily living.
Low-level singular concepts: Not alone 
sufficient to be an instrument used for a 
claim of treatment benefit
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Family 1 (F1) Family 2 (F2)
Aggregate
Specific F1 Specific F2
Level 1
Level 2
Level 4
Level 3
Order 0 - 1
Order 7 - 8
Figure 2 Patient-reported outcome instrument hierarchy: depicts concepts, measurement structure, and relationship to hierarchy.
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As shown in this ﬁgure, an aggregate is a compound concept
that explicitly includes multiple families, for example, HRQoL.
A global concept includes one or more families that are implicitly
deﬁned and aggregated by the patient, for example, self-rating
of health, and is outside the scope of a classiﬁcation system
that is based on clearly identiﬁed concepts and their explicit
relationships.
The main organizing unit for specifying one or more concepts
is the family. Each concept must belong to one family and,
conversely, each family can have few or many singular concepts.
In fact, a very simple depiction of the PRO Concept Taxonomy
can contain one singular concept within a single family in a given
application, for example, arthritis-speciﬁc pain within the HAQ.
More complex, single-family concepts may have low-level singu-
lar concepts that are used to form singular concepts. Singular
concepts may be used to form compound concepts if the instru-
ment development process provides empiric evidence that the
compound concept is deﬁned by the singular concepts.
Procedures for identifying PRO concepts and their relation-
ships are referenced in the FDA draft PRO guidance and docu-
mented in other publications [27–31]. These established methods
reﬂect the importance of using both qualitative and quantitative
techniques to assure that an instrument provides a suitable
measure of the intended measurement goal. Instruments devel-
oped using such procedures are most likely to contain items and
domains that adequately represent the concepts that are mean-
ingful to both patient and health-care professional, and to incor-
porate an approach to measurement that creates scores
appropriate for the intended use, for example, as clinical trial end
points.
Consideration of these PRO Concept Taxonomy principles
can assist in depicting an instrument’s conceptual framework. By
comparing an instrument’s taxonomic structure with a product’s
targeted labeling claims, the adequacy or an instrument can be
assessed and researchers can gain insights into the additional
instrument development work needed to support those claims.
Insight into the complexity of a concept can also be useful when
designing studies to support claims related to that concept.
The PRO Instrument Hierarchy
The second step in specifying an instrument’s conceptual frame-
work is to formalize relationships between concepts through the
identiﬁcation of the measurement structure and scoring system
and verify this against the measurement goals and the targeted
claim. Our review of approved labeling indicated that, regardless
of taxonomic structure, instruments could be grouped into nine
categories, representing increasing orders of conceptual and mea-
surement complexity. Table 1 shows the nine orders in the hier-
archy in terms of their number of families and concepts, and
measurement structure, along with examples to illustrate the type
of PRO instrument in each order. As indicated in columns 2 and
3, multiple-family instruments may be made up of singular or
compound concepts within the individual families. The number
and type of families and concepts within an instrument varies
depending on the intended use of the instrument. Some instru-
ments with multiple families may also permit the formation of an
aggregate concept that may support a claim of “health-related
quality of life” (HRQoL) if the included concepts meet the FDA’s
HRQoL deﬁnition [1]. A multifamily instrument may have a
validated measurement structure that permits it to support end
points of more than one order, depending on the concepts chosen
as study end points (e.g., the 36-Item Short-Form Health Survey
[SF-36]; see below).
Order 0 categorizes the simplest type of conceptual framework
and Order 8 categorizes the most complex. All PRO instruments,
whether generic, disease speciﬁc, treatment speciﬁc, or global,
belong to at least one family and thus can be placed in at least one
order in this hierarchy. Each order is also characterized by a
measurement structure that indicates the degree to which scores
for singular concepts can be combined to form higher-level scores.
Thus, each instrument score (or set of scores) becomes a study end
point and the concept represented by that score, or set of scores,
determines the particular order in the hierarchy that score is
assigned. PRO measures that are based on patient reports of
frequencies or occurrences of disease- or treatment-related events
are classiﬁed in Order 0. Instruments that record patients’ evalu-
ative responses, for example, severity or bothersomeness, about
symptoms, functions, or perceptions are placed in Orders 1–8.
Measures that assess a frequency count as a singular concept
in one family, such as the number of stools observed in the past
week, are classiﬁed into Order 0 and support very speciﬁc state-
ments about treatment effect. Instruments that elicit a patient’s
evaluation of a singular concept in one family are classiﬁed into
Order 1; like instruments in Order 0, these also support very
speciﬁc statements about treatment effect. The measure of ocular
itching in ALAMAST labeling is an example of an Order 1
instrument.
Global item measures are placed in Order 2 as each assesses
a compound, rather than a singular, concept. Global item mea-
sures provide general information that is difﬁcult to use as the
only evidence to support a clinical decision. They are included in
the PRO Instrument Hierarchy, however, as they have frequently
appeared in labeling, especially those for treatments of rheuma-
toid arthritis.
PRO measures in Order 3 assess singular concepts within one
family measured as a battery. Order 3 instruments differ from
those in Order 1 in that the singular concepts are clustered
together in labeling in some explicit way, such as in the measure-
ment of “time to symptom improvement” or in the need to
“win” simultaneously on a cluster of symptoms. The battery of
instruments measuring four migraine symptoms in IMITREX
labeling (Table 1) is an example of an Order 3 measure. These
measures support symptom-speciﬁc statements of treatment
beneﬁt and when taken into consideration altogether implicitly
demonstrate, rather than explicitly measure, treatment beneﬁt at
the family level (e.g., migraine symptoms).
Order 4 measures support statements of treatment beneﬁt
based on both the singular concepts and the family, as illustrated
by the excerpt from ARAVA labeling in Table 1. Instruments in
Order 4 have a measurement structure that provides a proﬁle of
scores that allows for meaningful interpretation when comparing
scores across domains throughout the duration of treatment.
Order 5 measures have four levels within one family and can
support statements of treatment beneﬁt at three levels, namely,
the singular and compound concept as well as the family levels.
Although no instruments of this type were found in our review of
approved labeling (see below), we include it for completeness.
Orders 6–8 instruments include two or more families with
two or more concepts. Like Order 4 instruments, these instru-
ments also generate proﬁles of scores that can support measure-
ment of concepts at various levels and offer multiple study design
and analysis options. Order 6 instruments, like those in Order 3,
measure individual concepts, but unlike Order 3, the concepts in
Order 6 instruments have a measurement approach, for example,
summated ratings, that allows for comparisons between the
family concepts; the SF-36 proﬁle is an example of an Order 6
instrument [32]. Order 7 measures combine multiple singular or
compound concepts into families or an aggregate that includes
A PRO Concept Taxonomy and Instrument Hierarchy 1161
Table 1 PRO instrument hierarchy for classifying PRO instruments according to their taxonomic and measurement structures, with examples of PRO
instruments and statements of treatment beneﬁt from existing prescription drug labeling
Order
number
Characterization of PRO instruments
Claim(s) supported by instrument
With example of PRO statement of treatment beneﬁt*Families* Concepts*
Taxonomic and measurement structure
With example of PRO instrument or concept
0 1 1 S 1 or more items in a singular concept that assess
frequencies or occurrences that are disease or
treatment related
Example: Number of stools per week
Speciﬁc claim about the reported event
Example: “Patients on ZELNORM also experienced an increase
in median number of stools from 3.8/week to 6.3/week at
month 1 . . .”
1 1 1 S 1 or more items eliciting patient evaluation of either a
symptom, function, or perception
Example: Ocular itching
Speciﬁc claim about the evaluated singular concept
Example: “ALAMAST was signiﬁcantly more effective than
placebo after 28 days in preventing ocular itching
associated with allergic conjunctivitis.”
2 1+ 1 C A global, compound concept measured by a single item
Example: Overall rating of the condition of dry mouth now
compared with before starting treatment
General claim that reﬂects the content of the item
Example: “Statistically signiﬁcant global improvement in the
symptoms of dry mouth was seen . . .” (EVOXAC)
3 1 2+ S Multiple singular concepts representing a cluster of
disease-related concepts with one or more
measurement approaches that allow for individual
concept scores.There is no family score.
Example: Headache response deﬁned in terms of severity
of headache pain. Associated symptoms of nausea,
photophobia and phonophobia were also assessed.
Concept-speciﬁc claims but no family-level claim.There
are as many claimable end points as there are concepts.
Example: “The percentage of patients achieving headache
response 2 and 4 hours after treatment was signiﬁcantly
greater among patients receiving IMITREX. For patients
with migraine-associated nausea, photophobia and/or
phonophobia at baseline, there was a lower incidence of
these symptoms at 2 hours (Study 1) and at 4 hours
(Studies 1,2, and 3).”
4 1 2+ C Singular concepts are expressed in 2+ singular concepts
with a measurement approach that allows for a
compound family score. Concept and family scores are
measured using a scoring system that allows direct
comparison of concepts.
Example: Health Assessment Questionnaire Disability Index
(HAQ DI)
Both concept-speciﬁc and family-level claims.There are at
least three claimable end points.
Example: “The mean change from baseline in functional ability
as measured by the HAQ Disability Index (HAQ DI) in the
6 and 12 month placebo and active controlled trials is
shown in Figure 4. ARAVA was statistically superior to
placebo in improving physical function. Superiority to
placebo was demonstrated consistently across all eight HAQ
DI subscales (dressing, arising, eating, walking, hygiene,
reach, grip and activities) in both placebo controlled
studies.”
5 1 1+ C and
1+ S
Compound concepts each have at least one subconcept
with a measurement approach that allows for the
calculation of subconcept and concept scores as well as
a family score. Both concept and family scores
represent compound concepts.
Example: None found
One family, and concept and subconcept claims; there are
as many claimable end points as there are end points in
the three levels.
Example: None found in labeling 1997–2007
6 2+ 2+ S Multiple singular concepts, each of which represents a
family, with a measurement approach that allows
comparison across concepts.There is no aggregate
score.
Example:Walking Impairment Questionnaire (WIQ)
Concept-level claims.There are as many claimable end
points as there are concepts.
Example: “TheWalking Impairment Questionnaire assesses the
impact of a therapeutic intervention on walking ability. In a
pooled analysis, patients reported improvement in their
walking speed and walking distance. (PLETAL).”
7 2+ 2+ S
or C
Concepts are measured in terms of 2+ concepts and 2+
families with a measurement approach that allows
calculation of concept and family scores that can be
compared.There is an aggregate score that combines
more than one family but omits at least one major
family needed to support the HRQoL concept.
Example: Asthma Quality of Life Questionnaire
(AQLQ—Juniper)
Family and concept-level claims, with as many claims as
there are families and concepts
Example: “The subjective impact of asthma on patient’s
perception of health was evaluated through use of the
AQLQ. Patients receiving ADVAIR DISKUS 100/50 had
clinically meaningful Improvements in overall asthma-speciﬁc
quality of life as deﬁned by a difference between groups of
at least 0.5 points in change from baseline.”
8† 3+ 3+ C Family and concept scores measurement approach that
allows comparison across families and concepts.There
is an aggregate score that includes all families needed
to support the HRQoL concept.
Example: Sickness Impact Proﬁle (SIP)
An overall (potentially HRQoL), as well as multiple family
and concept claims; there are as many claimable end
points as in the three levels plus the aggregate score.
Example: “The SIP, a multiitem scale in 12 concepts designed
to assess the patient’s functioning in multiple areas. Data
for the overall SIP score at baseline and change from
baseline at 3 months are presented in table 2. For TASMAR,
the change from baseline was statistically signiﬁcant for the
200 mg tid treatment arm, with a p-value of 0.01.”
C, compound concept; HRQoL, health-related quality of life; PRO, patient-reported outcome; S, singular concept.
*Labeling statements are taken from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ [46], the 2002 or the 2006 PDR [47].
†Any instrument or battery of instruments that provides an overall score without documentation that supports an underlying theoretical model or justiﬁcation for combining multiple families
of concepts should not present the overall score for decision-making. If such a score is used, a caveat about the lack of an appropriate measurement structure should be stated in a footnote.
NOTE:The examples in this table are drawn from the review of new prescription drug labeling approved between 1997 and 2002.These examples illustrate relationships between statements
of treatment beneﬁt and the measurement structures of various instruments.They do not, however, provide assurance that the same relationships will be applied to future drug approvals.
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more than one family; these instruments can be used to measure
both the concepts and the families. In addition, Order 7 instru-
ments may be used to measure the concept represented by the
aggregate score.
Order 8 measures are the most “complex,” both conceptually
and practically, because they: 1) measure three or more families,
including all families needed to support the HRQoL concept as
speciﬁed in FDA’s draft guidance, i.e., physical, psychological/
emotional, and social functioning; 2) have multiple domain
scores; and 3) incorporate measurement approaches that support
the calculation of an aggregate score. Order 8 instruments can be
used to measure singular concepts, family concepts, or aggregate
concepts. A conclusion that a treatment impacts HRQoL would
be based on an Order 8 instrument.
Depicting the Conceptual Framework
The conceptual framework of a battery of instruments proposed
for evaluating the beneﬁt of a new migraine treatment, that is, an
Order 3 battery of instruments, is illustrated in Figure 3 using the
taxonomy and hierarchy. The ﬁrst step in developing this frame-
work is to identify a set of signs and symptoms related to
migraine headache that are recognized by patients and clinicians
as being meaningful for deﬁning migraine treatment response.
The resulting speciﬁc family of migraine symptoms is represented
by a cluster of ﬁve singular concepts, shown as the taxonomic
structure in Figure 3. The dashed lines connecting the singular
concepts to the family level indicate that relationships between
the individual symptoms and the family, the measurement struc-
ture, are implied rather than explicit, that is, the scoring system
for the ﬁve symptoms does not include a combined symptom
score at the family level. In this example, a conclusion concerning
a treatment beneﬁt (migraine response) would be based on
improvement in every symptom depicted in the conceptual
framework.
Figure 4 shows the use of the taxonomy and hierarchy to
depict the conceptual framework of the HAQ-DI for supporting
labeling claims at both the family and compound concept levels,
an instrument in Order 4. As shown in this ﬁgure, the HAQ-DI
measures a speciﬁc family, deﬁned by the eight singular concepts,
which are, in turn, composed of low-level singular concepts. The
solid lines indicate that the instrument’s measurement structure
provides a rationale for combining low-level singular concepts to
form explicit statements about patient performance of eight sin-
gular concepts as well as the compound concept of physical
disability, which is expressed in a single score within the family of
arthritis-related physical function.
In developing both the taxonomy and hierarchy, we started
with the evaluation of a given instrument according to its
content, measurement structure, and scoring system. This
process produces a depiction of the conceptual framework as
illustrated in Figures 3 and 4. The orders in the PRO Instrument
Hierarchy also indicate the type of claim that the instrument can
support.
Evaluating the PRO Instrument Hierarchy
Using Recently Approved Labeling
The explicit relationships between the PRO instrument’s concep-
tual content, expressed in terms of the PRO Concept Taxonomy,
and the treatment beneﬁt statements in labeling, reﬂected in the
PRO Instrument Hierarchy, were evaluated and validated in two
separate stages. A previous analysis showed that labeling for 64
(30%) of the 215 new drugs approved from 1997 to 2002
included a treatment beneﬁt statement (in the Clinical Studies
section) about a concept measured by a PRO instrument [20]. We
ﬁrst reanalyzed the labeling for these 64 drugs, and classiﬁed the
conceptual frameworks represented by the PRO statements
therein into one of the nine categories described in Table 1.
During this ﬁrst stage, the PRO Instrument Hierarchy was
adapted to better ﬁt the actual labeling statements observed. To
validate this hierarchy, we then analyzed the labeling of the 142
new drugs approved in 2003–2007 (following the same criteria
used in the 1997–2002 study), of which 36 contained PRO-based
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statements in their Clinical Studies section, to determine whether
those statements and their implied conceptual frameworks
mapped well into the hierarchy. This second mapping determined
that no changes to the basic structure of the hierarchy were
needed, but we felt it was appropriate to modify the description
of Order 4, from “There are at least 3 claimable end points” to
“This may allow 3 or more claimable end points.”
The percentage of times that each order occurred, for each of
the two periods examined, is shown in Figure 5. Percentages add
to more than 100% because the labeling for many drugs (38 of
100) contains more than one order of PRO statement. For some
orders, the rate of use was similar between periods, in others it
was not; some of the variation observed is due to differences in
types of drugs approved between periods, as described below.
Simple event counts (Order 0) and singular PRO concepts
measured with one or more items (Order 1) were the most
commonly occurring orders, present in labeling for 40 and 52 of
the 100 drugs, respectively. Some frequently used event counts
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were cough (immunologic agents), partial seizure frequency (anti-
epileptic agents), and use of rescue medications (antimigraine and
respiratory agents). Frequently used singular PRO concepts were:
pain intensity, symptom assessments (several areas), ocular itching
(ophthalmics), and dyspnea (cardiovascular).
PRO concepts of Order 2 (global concepts), Order 3 (a cluster
of singular concepts), and Order 4 (1 family represented by one
compound concept containing 2+ singular concepts) were the
next most common, appearing in labeling for 25, 18, and 16
different drugs, respectively. Global concepts were most common
for anti-inﬂammatory agents, as a patient global score is part of
the American College of Rheumatology 20/50/70 criteria used in
rheumatoid arthritis; these accounted for the labeling of 10 drugs
out of the 26 with global scores [33,34]. Other statements clas-
siﬁed as globals were: time spent in on-off states for Parkinson’s
disease (ﬁve cases); ability to perform normal activities; and
satisfaction with treatment. Interestingly, global items were
rarely the only PRO concept in labeling (4 out of 26 cases).
Global concepts were less common in labeling approved between
2003 and 2007, primarily due to only one drug for rheumatoid
arthritis being approved during that period.
Order 3 PRO measures (which measure a cluster of singular
concepts) were most common among gastrointestinal agents
and antimigraine products, where different symptom concepts
(e.g., phonophobia, photophobia, nausea) are clustered together
as a single disease-speciﬁc family of concepts (migraine symp-
toms). Use of Order 3 instruments was much higher in the
1997–2002 than in 2003–2007 due to the approval of 6
migraine drugs in the earlier period, all with Order 3 PRO
measures, as opposed to no migraine drugs in the later period.
In the earlier period, all but one of the approvals based on
Order 4 measures referenced the HAQ Disability Index (or
M-HAQ) for anti-inﬂammatory products [23,35]; the only
other Order 4 instrument was the total nasal and non-nasal
symptom score for a respiratory product. In the later period,
however, there was more varied use of Order 4, including the
Erectile Function domain of the International Index of Erectile
Dysfunction, the Functional Living Index—Emesis, the Sheehan
Disability Scale, and the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Inventory (ADCS-ADL)
[36–39].
More complex PRO measures were less common, with no
examples of Order 5 instruments occurring in this set of labeling,
and a total of 21 examples with Order 6–8 measures. Order 6
measures (2+ families represented by 2+ singular concepts with a
proﬁle of scores) included the Walking Impairment Question-
naire (cardiovascular agents), the SF-36 proﬁle of scores (diag-
nostics), the Quality of Life in Narcolepsy [40], the Toronto
Western Spasmodic Torticollis Rating Scale (TWSTRS) [41]
(central nervous system agents), and the International Index of
Erectile Function [36] (urologic agents). The SF-36 proﬁle of
scores was the only Order 6 PRO measure during 2003–2008,
used for the lone antiarthritis drug approved in the later period.
Examples of Order 7 PRO measures (2+ families represented
by 2+ singular or compound concepts, allowing for family or
aggregate scores) also primarily occurred for anti-inﬂammatory
products, based on the SF-36 Physical Component Score (PCS)
and Mental Component Score (MCS) scores or the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) composite score [42]; one was based on the total
score of the Fibromyalgia Impact Questionnaire [43]. The two
examples of an Order 8 PRO measure (3+ families, 3+ concepts,
with an aggregate score) were the sickness impact proﬁle [44]
total score, used for an anti-Parkinsonian product, and a claim
for “improved health-related qualify of life” for treatment for
paroxysmal nocturnal hemoglobinuria, based on results of the
European Organization for Research and Treatment of Cancer
Quality-of-Life Questionnaire–30-items (EORTC-QLQ-C30)
[45].
In reviewing these results across orders and time periods,
there has been relatively less frequent use of Orders 2–8 since
2003. Of those drugs approved in 1997–2002 with PROs in their
labeling, 59% (38/64) included at least one PRO of Order 2–8,
while in 2003–2007, 42% (15/36) included at least one PRO of
Order 2–8. Much of this difference is due to the nature of the
drugs approved during these periods—in the earlier period, 15
arthritis or migraine drugs were approved, all having these
higher-order PROs, while in the latter period, only one arthritis
or migraine drug was approved. Not including those drugs in this
comparison results in 47% (23/49) labels from 1997–2002 with
Order 2–8 PRO’s, and 40% (14/35) in 2003–2007.
This analysis indicates that instruments that have commonly
been used in the drug approval process ﬁt within the nine orders
in the PRO Instrument Hierarchy, based on both an evaluation
and a validation labeling sample. This ﬁnding provides evidence
for the relevance of both the taxonomy and hierarchy in charac-
terizing PRO instruments to be used in clinical trials. Most of the
PRO data led to statements of treatment beneﬁt within one
family rather than multiple families, with over half being used to
make narrow statements of treatment efﬁcacy, that is, based on
singular concepts that did not explicitly include a statement of
family-level beneﬁt.
Discussion
Speciﬁc terminology and the PRO Concept Taxonomy and PRO
Instrument Hierarchy are proposed as approaches for more sys-
tematically establishing and evaluating conceptual frameworks
for PRO instruments used in trials to assess clinical beneﬁt.
Beyond providing structures for characterizing PRO measures,
they supply outcomes researchers with tools for evaluating and
explaining an instrument’s conceptual framework within the
context of a speciﬁc claim. With improved clarity of this struc-
ture, the linkage between the underlying diagnostic or conceptual
terminology and the outcome of the health-care intervention
becomes stronger and more transparent.
The drug-approval process is unique in that it explicitly links
the use of a PRO instrument to medical decision-making through
a statement of treatment beneﬁt. The PRO Concept Taxonomy
and PRO Instrument Hierarchy are proposed as structures for
clarifying this linkage and for locating the use of well-established
and relevant psychometric methods within this process. For
example, use of these methods to demonstrate an instrument’s
content validity within the context of the intended claim is part
of the depiction of an instrument’s concept taxonomy. Similarly,
depiction of an instrument’s measurement structure is deter-
mined by use of well-established quantitative psychometric
methods which, in turn, locate the instrument within the PRO
Instrument Hierarchy, thereby indicating its suitability for the
intended claim.
The review of 1997–2002 new drug labeling illustrated that
the PRO Instrument Hierarchy, incorporating the principles of
the PRO Concept Taxonomy, is relevant across a wide range of
both therapeutic products and the measures chosen to demon-
strate their clinical beneﬁt; this ﬁnding was conﬁrmed by a sub-
sequent review of 2003–2007 new drug labeling. For example,
the predominance of the use of simple PRO instruments—event
counts and singular concept PRO instruments (Orders 0 and
1)—along with global items and disease-speciﬁc, single-family
PRO instruments (Orders 2 and 3) ﬁts with the speciﬁc state-
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ments about treatment beneﬁt. Aside from the global PRO
instruments, which are rarely used in isolation, the connection
between the PRO instrument and the disease or its treatment is
probably most transparent in these cases and the underlying
conceptual framework of the instrument need not be complex.
Use of instruments with multiple concepts was much less
common, particularly outside the antiinﬂammatory area, sug-
gesting that establishing a clear relationship between treatment
of a speciﬁc disease and broader PRO concepts can be more
challenging, both in theory and in practice. Nevertheless, there
are sufﬁcient examples of measures with multiple concepts and
families to indicate the relevance of the taxonomy and hierarchy
and to establish the potential value of measures based on
complex concepts. Use of the hierarchy along with the concept
taxonomy, beyond simply allowing for a better understanding of
the full spectrum of PRO statements allowed in labeling over this
11-year period, should assist in making the determination when
to consider and justify the use of more comprehensive measures.
Characterizing PRO instruments in a standardized way may
improve not only the communication between industry and its
regulators but also within the research community more
broadly. For example, abstracts of clinical studies frequently
use terms such as pain, physical function, and HRQoL to
describe measures that may represent any of the orders in the
hierarchy. Unless the abstract speciﬁcally names the instruments
used, the reviewer must locate the article to fully understand
both the concepts being measured and the conceptual frame-
work of the instrument in order to interpret the ﬁndings. Even
within an article, the exact concept(s) measured may be incom-
pletely documented, leading to misinterpretation of ﬁndings.
More careful attention to the naming of concepts with consid-
eration for the PRO Concept Taxonomy and PRO Instrument
Hierarchy will help to clarify the results of clinical studies using
PRO instruments.
The work presented here is limited in several ways. First,
our approach has been heavily inﬂuenced by use of PRO’s in
new drug labeling and hence may not be as applicable to other
areas using PRO’s. Second, it has been based on retrospective
evaluation of instruments and labeling; prospective use may,
and is in fact likely to, generate new considerations that could
affect the proposed taxonomy and hierarchy. Third, while we
have acknowledged the important role of measurement science,
especially that of content validity, in the developing a concep-
tual framework, we have yet to explicitly incorporate this work
into our speciﬁcation of the two tools. And, perhaps most
importantly, our approach has not yet been used, to the best
our knowledge, in any interactions between sponsors and regu-
lators, nor has it been explicitly endorsed by any regulatory
agency.
Finally, the terminology, taxonomy, and hierarchy described
above are proposed as a way of improving clarity and consis-
tency when studies intended to evaluate therapeutic impact
are conceived, developed, evaluated, and communicated. It
draws both from the existing theoretical literature and from
what has been observed in approved labeling and in the regu-
latory setting. Nevertheless, reﬁnements and extensions to
improve the taxonomy and hierarchy to meet future needs are
both encouraged and expected. The overriding goal is to better
incorporate the most relevant and interpretable PRO measures
into drug development, drug labeling, and ultimately, patient
care.
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